Abstract:
:The study was aimed to explore the efficacy and safety of allo-HSCT with high-dose cyclophosphamide-induced immune tolerance for SAA. In the present study, 20 cases (12 male, 8 female; average age = 17.8 years) received reduced-intensity conditioning allo-HSCT from August 2012 to August 2014 in the Beijing Military Region General Hospital. All were HLA mismatched and received CSA; 11 received ATG-intensive immune therapy. Donors underwent mobilization with cell colony-stimulating factor. The modified preconditioning regimen included reduced-strength fludarabine combined with Busulfex and cytarabine, cyclophosphamide. Cyclophosphamide (50 mg/kg/d) induced immune tolerance 3 days after transplantation and was combined with immunosuppressive agents, including CSA, MTX, and FK506, for GVHD prophylaxis and the management of observed toxicity, GVHD and DFS. Hematopoietic reconstitution was achieved in 17 cases and engraftment after a second transplantation in an additional three cases. The average times to engraftment were 17.4 and 21.3 days, respectively, with neutrophils ≥0.5 × 109/L and platelets ≥20 × 109/L. Engraftment was confirmed by the evidence of 100 % donor hematopoiesis; T lymphocyte subset counts also increased significantly after transplantation. During follow-up monitoring to April 2015 (median duration = 17.7 months), three patients died of complications, while the other 17 showed disease-free survival (DFS rate = 85 %; longest DFS period = 32 months). Reduced-intensity allo-HSCT with high-dose cyclophosphamide-induced immune tolerance treatment is effective for SAA and can be the key technology extensively used in clinic, but its efficacy needs to be confirmed further with prospective randomized study with increased sample size.
journal_name
Int J Hematoljournal_title
International journal of hematologyauthors
Guo Z,Gao HY,Zhang TY,Liu XD,Yang K,Lou JX,He XP,Zhang Y,Chen P,Chen HRdoi
10.1007/s12185-016-2106-zsubject
Has Abstractpub_date
2016-12-01 00:00:00pages
720-728issue
6eissn
0925-5710issn
1865-3774pii
10.1007/s12185-016-2106-zjournal_volume
104pub_type
杂志文章abstract::The present study (ClinicalTrials.gov Identifier: NCT02221492) was conducted to assess the efficacy and safety of plerixafor for the mobilization and collection of haematopoietic stem cells (HSCs) for autologous transplantation in Japanese non-Hodgkin lymphoma (NHL) patients. In this randomized phase 2 study, patients...
journal_title:International journal of hematology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1007/s12185-018-2505-4
更新日期:2018-11-01 00:00:00
abstract::Perioperative hemostatic management is a challenge in patients with Glanzmann thrombasthenia (GT). The standard means of preventing surgical bleeding in GT patients is platelet transfusion. However, GT patients often possess alloantibodies against GPIIb/IIIa and/or HLA, which cause resistance to platelet transfusion. ...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-016-2096-x
更新日期:2017-02-01 00:00:00
abstract::Recent evidence suggests that mesenchymal stem cells (MSC) selectively home to tumors, where they contribute to the formation of tumor-associated stroma. This effect can be opposed by genetically modifying MSC to produce high levels of anti-cancer agents that blunt tumor growth kinetics and inhibit the growth of tumor...
journal_title:International journal of hematology
pub_type: 杂志文章,评审
doi:10.1532/IJH97.06230
更新日期:2007-07-01 00:00:00
abstract::To investigate the expression of activation molecules on CD5(+)B lymphocytes in peripheral blood of autoimmune hemolytic anemia (AIHA)/Evans patients. The expression of CD80, CD86, and CD69 on CD5(+)B lymphocytes was detected using flow cytometry in 30 AIHA/Evans patients, 18 normal controls (NC) and nine chronic lymp...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-016-1964-8
更新日期:2016-05-01 00:00:00
abstract::Bortezomib is a proteasome inhibitor demonstrating substantial activity in multiple myeloma. One of its key toxicities is peripheral neuropathy, which is reversible in most patients. The possibility that bortezomib might in rare cases induce severe neuropathies by auto-inflammatory mechanisms remains controversial. We...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-011-0847-2
更新日期:2011-06-01 00:00:00
abstract::Intravenous immunoglobulin (IVIG) therapy has been used for autoimmune diseases and disorders involving autoantibodies, including coagulation inhibitors. In this review, we have evaluated the efficacy and safety of IVIG therapy for acquired coagulation inhibitors, including factor VIII inhibitor, and for acquired von ...
journal_title:International journal of hematology
pub_type: 杂志文章,评审
doi:10.1532/IJH97.06222
更新日期:2007-05-01 00:00:00
abstract::Neurological complications in thrombotic thrombocytopenic purpura (TTP) are associated with poor prognosis and/or permanent damage. We report a young woman in whom the diagnosis of TTP was difficult because cardinal manifestations were absent at presentation. The patient relapsed, showing severe and dramatic neurologi...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:
更新日期:2000-02-01 00:00:00
abstract::We herein report on the current status of Japanese HIV-positive patients with coagulation disorders, primarily hemophilia, based on the national survey of 31 May 2006. The total number of registered patients was 1,431 (Hemophilia A 1,086; Hemophilia B 325; von Willebrand disease 8; others 12), and 604 of these patient...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-008-0144-x
更新日期:2008-10-01 00:00:00
abstract::In addition to reduced-intensity conditioning, which has expanded the eligibility for hematopoietic cell transplantation (HCT) to older patients, increased availability of alternative donors, including HLA-mismatched unrelated donors, has increased access to allogeneic HCT for more patients. However, acute graft-versu...
journal_title:International journal of hematology
pub_type: 杂志文章,评审
doi:10.1007/s12185-013-1421-x
更新日期:2013-09-01 00:00:00
abstract::The heterogeneity of bone marrow plasmacytosis is clearly analyzed by multicolor staining with anti-CD38 antibody. To date, at least 5 subpopulations of plasma cells have been identified in the bone marrow of multiple myeloma (MM) patients with regard to the expression of MPC-1, CD49e (VLA-5), and CD45: MPC-1(-)CD49e(...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1532/IJH97.05112
更新日期:2006-01-01 00:00:00
abstract::A pilot phase I/II study was conducted as a single-institute trial for evaluation of the feasibility and efficacy of a new salvage chemotherapy, CHASE, for patients with refractory or relapsed lymphoma . The CHASE regimen, consisting of cyclophosphamide, cytosine arabinoside, etoposide, and dexamethasone, was administ...
journal_title:International journal of hematology
pub_type: 临床试验,杂志文章
doi:10.1007/BF02986620
更新日期:2003-06-01 00:00:00
abstract::In order to better understand the biology of adult T cell leukemia (ATL), we aimed to establish a novel method, which allows the primary growth of ATL cells using a co-culture system with murine bone marrow-derived stromal cells, MS-5. ATL cells grew in close contact with MS-5 layers and formed so-called "cobblestone ...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-008-0207-z
更新日期:2008-12-01 00:00:00
abstract::GATA transcription factors have been shown to play important roles in hematopoiesis. GATA-2 is expressed in stem and progenitor cells, and has been speculated to control the proliferation and maintain the immaturity of these cells. To examine whether the function of GATA-2 is changeable according to the differentiatio...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1532/IJH97.06020
更新日期:2006-07-01 00:00:00
abstract::Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in pregnant women. Enoxaparin is a low-molecular-weight heparin used during pregnancy to treat or prevent VTE. In this study, we compare anti-factor Xa peak levels in pregnant and non-pregnant women, and explore the association between anti-fac...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-020-02873-2
更新日期:2020-07-01 00:00:00
abstract::Common variable immunodeficiency (CVID) is a highly heterogeneous disease with an unpredictable pattern. CVID appears to have an immunologic and clinical phenotype similar to some hereditary humoral immunodeficiencies, including X-linked lymphoproliferative disease (XLP). The differential diagnosis of CVID and XLP is ...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/BF02983239
更新日期:2003-07-01 00:00:00
abstract::The objective of present study was to compare the prognosis of diffuse large B-cell lymphoma (DLBCL) with Waldeyer's ring involvement (WR-DLBCL) to that of nodal DLBCL (N-DLBCL) without WR involvement. Between July 2004 and October 2009, medical records and metabolic tumor volume (MTV) measured by 2-[fluorine-18]-fluo...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-013-1282-3
更新日期:2013-03-01 00:00:00
abstract::This observational study aimed to assess real-world treatment patterns and clinical outcomes for patients with chronic immune thrombocytopenia (ITP) currently being treated with eltrombopag or romiplostim after switching from corticosteroids, rituximab, or the alternate thrombopoietin receptor agonist (TPO-RA). The st...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-014-1731-7
更新日期:2015-03-01 00:00:00
abstract::TAL1/SCL is a prime example of an oncogenic transcription factor that is abnormally expressed in acute leukemia due to the replacement of regulator elements. This gene has also been recognized as an essential regulator of hematopoiesis. TAL1 expression is strictly regulated in a lineage- and stage-specific manner. Suc...
journal_title:International journal of hematology
pub_type: 杂志文章,评审
doi:10.1007/s12185-018-2518-z
更新日期:2019-01-01 00:00:00
abstract::Autoimmune hemolytic anemia (AIHA) is a rare comorbidity in colorectal cancer (CRC) and has an unknown etiology. Previously, we described an AIHA case secondary to CRC with ectopic band 3 expression. Herein, we investigated ectopic band 3 expression and erythrocyte membrane-bound IgG in a CRC cohort. Between September...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-020-02831-y
更新日期:2020-05-01 00:00:00
abstract::Acute myeloid leukemia (AML) is predominantly a disease of older adults, with a median age at diagnosis of over 65 years. AML in older adults differs biologically and clinically from that in younger ones, and is characterized by stronger intrinsic resistance and lower tolerance to chemotherapy. The effects of age on b...
journal_title:International journal of hematology
pub_type: 杂志文章,评审
doi:10.1007/s12185-012-1137-3
更新日期:2012-08-01 00:00:00
abstract::A 74-year-old female with seropositive rheumatoid arthritis developed severe bone marrow failure after the treatment with very low-dose methotrexate (5 mg/week for 3 weeks). Hematological data showed severe pancytopenia with 0% neutrophils and bone marrow disclosed thoroughly hypocellular marrow. Shortly after the tre...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1016/s0925-5710(96)00549-x
更新日期:1997-02-01 00:00:00
abstract::A 2-year-old Japanese boy who presented with multiple cervical, axillary, and inguinal lymphadenopathy was diagnosed by immunocytochemical analysis as having myeloid/natural killer (NK) cell precursor acute leukemia. Leukemic blasts in the bone marrow were positive for CD56 (NK marker), CD7 (T-cell marker), CD33 (myel...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/BF02982029
更新日期:2002-02-01 00:00:00
abstract::Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent for adult T-cell leukemia. The geographic distribution of HTLV-1 carriers is quite uneven in Japan and the greatest prevalence is in southwestern Japan. Because many people move from endemic areas to the greater Tokyo area, the geographic distributio...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-008-0209-x
更新日期:2008-12-01 00:00:00
abstract::Philadelphia (Ph) chromosome as a result of t (9; 22) (q34; q11) is observed in more than 90% of chromic myeloid leukemia (CML) patients. Cases in which the typical Ph chromosome is not visible at the karyotype level comprise 5-10% of CML patients. CML cases with fusion transcripts such as e13a3 in which ABL exon 3 ra...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-009-0368-4
更新日期:2009-09-01 00:00:00
abstract::Acute promyelocytic leukemia (APL) is characterized by t(15;17)(q22;q21), which results in the fusion of the promyelocytic leukemia (PML) gene at 15q22 with the retinoic acid alpha-receptor (RARA) at 17q21. We report a patient with APL carrying a new complex variant translocation (5;17;15;20). Spectral karyotyping ana...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-011-0929-1
更新日期:2011-10-01 00:00:00
abstract::B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma (BL) is a new entity in WHO classification 2008, and includes Burkitt-like transformation of follicular lymphoma (FL). However, the pathological significance of BCL-2/IgH translocation, which is chara...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-010-0741-3
更新日期:2011-01-01 00:00:00
abstract::We performed a retrospective population-based cohort study of acute myeloid leukemia (AML) in Miyazaki Prefecture, Japan. Over 6 years, we diagnosed 221 patients (211 adults and 10 children) with AML, indicating an incidence of AML in Miyazaki Prefecture of 3.2 per 100,000 per year. In 193 adult patients with non-acut...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-012-1146-2
更新日期:2012-09-01 00:00:00
abstract::A 50-year-old woman presented with CML-CP and was initially treated with branded imatinib (Glivec) 400 mg/day. She rapidly achieved a complete hematologic response (CHR), at which point she switched therapy to a copy version of imatinib (Imatib). She received 400 mg/day of Imatib for 3 months, during which time her pl...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-009-0431-1
更新日期:2010-01-01 00:00:00
abstract::We studied a 29-year-old Japanese male patient with factor XI deficiency; we also studied his parents and one sibling. Factor XI coagulation activity and antigen levels were extremely low (less than 1% of normal level) in both the patient and his brother, and they were half the normal levels in both parents. Sequence ...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:
更新日期:2000-01-01 00:00:00
abstract::We present the case of a 62-year-old Japanese woman with relapsed adult T-cell leukemia/lymphoma (ATLL) who was treated with humanized anti-CCR4 monoclonal antibody (KW-0761). Although this antibody was highly effective against refractory ATLL, 6 months after the final KW-0761 infusion, the patient complained of hypox...
journal_title:International journal of hematology
pub_type: 杂志文章
doi:10.1007/s12185-013-1278-z
更新日期:2013-03-01 00:00:00